Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The sensitivity of the PSA test as an indicator of the presence of prostate cancer is known to be about 80 to 90 percent. In lay terms, what this means is that 80 to 90 percent of men who actually have prostate cancer cells in their prostate will have an elevated PSA level compared to [...]
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, PSA, risk | 8 Comments »
Two patients we respect (who have very differing perspectives and experiences) have brought a new book to our attention — and it’s free! It’s called Let Sleeping Dogs Lie. To quote one of our correspondents, “It sets out the pros and cons of screening but does not rule out diagnostic testing. There is a difference between these [...]
Filed under: Diagnosis, Risk | Tagged: Diagnosis, risk, sc reening, testing | Comments Off
As if it wasn’t long enough already, the list of adverse events “associated with” the use of androgen deprivation therapy (ADT) in the treatment of prostate cancer is growing.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: ADT, adverse effect, androgen deprivation, colorectal, LHRH agonist, orchiectomy | 4 Comments »
Toremifene is a selective estrogen receptor modulator or SERM. Some time ago, its developer (GTx, Inc.) initiated a Phase III clinical trial to investigate whether toremifene at a dose of 80 mg/day lowered risk for new vertebral fractures in prostate cancer patients being treated with androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: benefit, fracture, Prevention, risk, toremifene | 2 Comments »
Paul Levy is the President and CEO of the Beth Israel Deaconess Medical Center in Boston (which is no small institution). He is not an enthusiastic advocate for the sudden growth in the number of proton beam radiation therapy (PBRT) centers in the US in the past 3 years. You want to see why, just [...]
Filed under: Management, Treatment | Tagged: cost, outcome, PBRT, proton, radiation therapy | Comments Off
No data have previously been available on the relationship between surgical experience, surgical volume and complication and transfusion rates in patients undergoing minimally invasive forms of radical prostatectomy (e.g., laparoscopic radical prostatectomy with or without robot assistance).
Filed under: Management, Treatment | Tagged: caseload, experience, laparoscopic, minimally invasive, radical prostatectomy | 2 Comments »
This is the immortal and clichéd phrase spoken by Tim Robbins playing Calvin “Meat” LaLoosh to the attractive young reporter as he starts his career in the Majors near the end of Bull Durham. And now we know that the meat isn’t as bad an actor (in the development of prostate cancer) as the reviewers [...]
Filed under: Diagnosis, Prevention, Risk | Tagged: meat, processed, red, risk | 5 Comments »
The idea that the soy isoflavone known as genistein might prove to be a non-toxic therapeutic agent for the prevention and/or treatment of prostate cancer has now been around for so long that the idea appears to have become a perceived truth in some quarters.
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: genistein, isoflavone, outcome, soy, trial | Leave a Comment »
There is a recognized risk for development of secondary primary cancers (SPCs) after first-line treatment with radiation therapy for localized prostate cancer. However, a new article suggests that newer forms of radiation therapy may have noticeably reduced that risk.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cancer, outcome, radiation, secondary | 6 Comments »
A new article on the WebMD web site appears under the heading “Targeted radiation may help men avoid impotence,” but it is the incidence of adverse genitourinary (GU) obstructive symptoms during and after treatment that is of greater interest to The “New” Prostate Cancer InfoLink.
Filed under: Management, Treatment | Tagged: adverse effect, erectile function, genitourinary, obstructive, ouctome, PBRT, proton beam, radiation | 5 Comments »
Small cell carcinoma of the prostate or SCCP is a rare, aggressive, and treatment-refractory form of prostate cancer. No good form of treatment is yet known for this disease, and median survival from initial diagnosis is less than 2 years.
Filed under: Management, Treatment, Uncategorized | Tagged: carcinoma, cisplatin, cisplatinum, irinotecan, small cell | 1 Comment »
We have known since 1994 that the recurrence of some types of cancer can be driven by cancer- specific stem cells (cancerous duplicates of the normal stem cells that we all carry in our bone marrow and our blood stream). Whether this is true of all cancers is definitively not known.
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: cell, recurrence, stem | Leave a Comment »
A “virtual biobank” is an electronic database of information about biological specimens and other related information, regardless of where the actual specimens are (or were) orginally found, studied, and actually stored. Such biobanks are increasingly valuable resources for specialized researchers.
Filed under: Uncategorized | Tagged: biobank, research, specimen, virtual | Leave a Comment »
Could serum testosterone levels predict the effectiveness of combined androgen deprivation (ADT2) — through addition of an antiandrogen — in men with progressive prostate cancer and a rising PSA on LHRH agonist therapy alone?
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: ADT, ADT2, androgen deprivation therapy, outcome, progression, survival | Leave a Comment »
A new paper by a multi-center research team has refined the long-held suspicion that some types of aggressive prostate cancer may be the consequence of the accumulation of multiple mutations in the patients’ DNA.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, fusion, gene, risk | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site